COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics to Participate in Upcoming Conferences
22/10/2018
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc . (NASDAQ: CAPR), is [...]
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
22/10/2018
- Pelareorep more than doubles overall survival at recommended phase two dose as compared to historical phase 3 data - CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ [...]
Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development
22/10/2018
REHOVOT, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business [...]
Auxly Announces Cultivation and Retail Expansion Into Newfoundland & Labrador Through Strategic Partnership With Atlantic Cultivation
22/10/2018
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (" Auxly " or the " Company ") is pleased to announce that the Company has entered into a binding [...]
Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings
22/10/2018
FREMONT, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical [...]
New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients
22/10/2018
SINGAPORE, Oct. 22, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in [...]
ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer
22/10/2018
BUFFALO, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018
22/10/2018
Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an [...]
CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting
22/10/2018
- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host Conference Call and Webcast Today, Monday, [...]
NICE publishes advice on gammaCore for the treatment of cluster headache
22/10/2018
Report contributors agreed gammaCore was innovative and it has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- [...]
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
22/10/2018
Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Dr. [...]
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
22/10/2018
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients who may not relapse [...]
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
22/10/2018
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix ® presented positive data for a [...]
Herantis Pharma Oyj: Manager's Transactions - Pekka Simula
22/10/2018
Herantis Pharma Oyj: Manager's Transactions - Pekka Simula Herantis Pharma Plc Company release 22 October 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person [...]
Rule 2.9 Announcement
22/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 22 October 2018 [...]
Director/PDMR Shareholding
22/10/2018
DXS INTERNATIONAL PLC Directors' Dealing The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm [...]
Award of Share Options
22/10/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Award of Share Options Oxford, UK, and Cambridge, MA, US, 22 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic [...]
DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
22/10/2018
Montrouge, France, October 22, 2018 DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration DBV Technologies (Euronext: DB - ISIN: FR0010417345 [...]
DBV Technologies annonce le dépôt de sa demande d'autorisation de mise sur le marché de produit biologique (BLA) pour Viaskin Peanut auprès de la Food and Drug Administration des États-Unis
22/10/2018
Montrouge, France, le 22 octobre (07h30 CEST), 2018 DBV Technologies annonce le dépôt de sa demande d'autorisation de mise sur le marché de produit biologique (BLA) pour Viaskin Peanut auprès de la Food and Drug [...]

Pages